Review Article
No access
Published Online: 17 December 2024

Cystic Fibrosis Lung Disease: An Overview

Publication: Respiratory Care
Volume 65, Issue Number 2

Abstract

Although better insights into the natural course of cystic fibrosis (CF) have led to treatment approaches that have improved pulmonary health and increased the life expectancy of individuals with this disorder, lung disease remains the main cause of morbidity and mortality in patients with CF. Evidence suggests that airway epithelial defects in ions-water transport lead to dehydrated mucus, impaired mucus clearance, and mucus adhesion to airway surfaces.

Abstract

Although better insights into the natural course of cystic fibrosis (CF) have led to treatment approaches that have improved pulmonary health and increased the life expectancy of individuals with this disorder, lung disease remains the main cause of morbidity and mortality in patients with CF. Evidence suggests that airway epithelial defects in ions-water transport lead to dehydrated mucus, impaired mucus clearance, and mucus adhesion to airway surfaces. An increase in mucin secretion is also suggested by the formation of endobronchial mucus plaques and plugs, which become the main sites of air flow obstruction, infection, and inflammation conducing to early small airways disease followed by the development of bronchiectasis. The lung involvement is usually progressive with intermittent exacerbations. Aggressive management and advances in treatment delay, but, do not prevent progression of lung disease. Respiratory failure ensues and is the major cause of death. The lung parenchyma is virtually untouched for much of the course of the disease. This review focuses on the lung involvement in cystic fibrosis and summarizes new developments on the diagnostic approach of CF and pathogenesis of related lung disease. Current therapeutic modalities, novel therapies targeting the basic genetic defect, and lung transplantation are also reviewed.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015;372:351–362.
2.
Rubin BK. Cystic fibrosis: myths, mistakes, and dogma. Paediatr Respir Rev 2014;15:113–116.
3.
Cystic Fibrosis Foundation Patient Registry Report 2016. Bethesda, MD: Cystic Fibrosis Foundation, 2017.
4.
Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183(11):1463–71.
5.
Ahmed NN, Durie PR. Nonpulmonary manifestations of cystic fibrosis. In: Wilmott, Boat, Bush, Chernick, Deterding, Ratjen. editors. Disorders of the respiratory tract in children. Philadelphia: Elsevier; 2012:781–795.
6.
Collins S. Nutritional management of cystic fibrosis: an update for the 21st century. Paediatr Respir Rev 2018;26:4–6.
7.
Faro A, Michelson PH, Ferkol TW. Pulmonary disease in cystic fibrosis. In: Wilmott, Boat, Bush, Chernick, Deterding, Ratjen. editors. Disorders of the respiratory tract in children. Philadelphia: Elsevier; 2012:770–780.
8.
Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017;181(Suppl 4):S4–S15.
9.
Strong TV, Smit LS, Turpin SV, Cole JL, Tom Hon C, Markiewicz D, et al. Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levels. N Engl J Med 1991;325(23):1630–1634.
10.
Feldmann D, Couderc R, Audrezet MP, Ferec C, Bienvenu T, Desgeorges M, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mut 2003;22(4):340.
11.
Cirilli N, Braggion C, Mergni G, Polizzi AM, Padoan R, Sirianni S, et al. May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for cystic fibrosis? J Pediatr 2018;194:261–262.
12.
Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, et al. Diagnosis of cystic fibrosis in nonscreened populations. J Pediatr 2017;181(Suppl 4):S52–S57.
13.
Boyle M, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013;1:158–163.
14.
Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis–analysis of the most common mutation (delta F508). N Engl J Med 1990;323(22):1517–1522.
15.
Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007;175(10):1036–1043.
16.
Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109(5):571–577.
17.
Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937–941.
18.
Boucher RC. Muco-obstructive lung diseases. N Engl J Med 2019;380:1941–1953.
19.
Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992–2001.
20.
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med 2017;377:911–922.
21.
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109(3):317–325.
22.
Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017;195:1384–1393.
23.
Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963–70.
24.
Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 2014;11(7):1120–1129.
25.
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010;23:(2):299–323.
26.
Cystic Fibrosis Foundation Patient Registry 2017. Bethesda, MD: Cystic Fibrosis Foundation, 2018.
27.
Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, et al. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome 2017;5(1):51.
28.
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91–100.
29.
Douglas TA, Brennan G, Gard L, Berry C, Gangell C, Stick SM, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009;33(2):305–311.
30.
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165(9):847–856.
31.
Rosenfeld M. Pseudomonas aeruginosa eradication. Commentary. eCystic Fibrosis Rev 2014;4(5).
32.
Ratjen F, Munck A, Kho P, Angyalosi G. ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65(4):286–291.
33.
Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 2017;16(3):395–400.
34.
Vidya P, Smith L, Beaudoin T, Yau YC, Clark S, Coburn B, et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2016;35:67–74.
35.
Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M. EPIC Study Group. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol 2015;50:42–48.
36.
LiPuma JJ. Understanding the microbiology of the CF lung. eCystic Fibrosis Rev 2016;6(3).
37.
Hector A, Kirn T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riethmueller J, et al. Microbial colonization and lung function in adolescents with cystic fibrosis. J Cyst Fibros 2016;15:340–349.
38.
Hoffman L. P. aeruginosa and S. aureus: a love-hate relationship. Pediatr Pulmonol 2017;52(Suppl 47):168.
39.
Caverly LJ, Zhao J, LiPuma JJ. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection. Pediatr Pulmonol 2015;50(Suppl 40):S31–S38.
40.
Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:2386–2392.
41.
Dasenbrook EC. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr Opin Pulm Med 2011;17:437–441.
42.
Vanderhelst E, De Meirleir L, Verbanck S, Piérard D, Vincken W, Malfroot A. Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cyst Fibros 2012;11:2–7.
43.
Lo DK, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2018;7:CD009650.
44.
Stanojevic S, Ratjen F, Stephens D, Lu A, Yau Y, Tullis E, Waters V. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013;12:575–583.
45.
Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality of lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013;12:482–486.
46.
Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, Raia V. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 2011;30(8):973–980.
47.
Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol 2002;51(7):533–538.
48.
Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, Elborn JS. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004;3(2):93–98.
49.
Bar-On O, Mussafi H, Mei-Zahav M, Prais D, Steuer G, Stafler P, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros 2015;14:53–62.
50.
Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881–886.
51.
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016;71(Suppl 1):i1–i22.
52.
Griffith DE, Aksami T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacteria diseases. Am J Respir Crit Care Med 2007;175(4):367–416.
53.
Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infection in cystic fibrosis. Clin Chest Med 2016;37:83–96.
54.
Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic fibrosis: updates and the path forward. Pediatr Pulmonol 2017;52(Suppl 48):S29–S36.
55.
Ratjen F, Water V. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst 2016;12;CD010004.
56.
Schoen L, Santoro JD, Milla C, Bhargava S. Pulmonary nocardiosis in an immunocompetent patient with cystic fibrosis. Case Rep Pulmonol 2015;2015:984171.
57.
Mei-Zahav M, Livnat G, Bentur L, Mussaffi H, Prais D, Stafler P, et al. The spectrum of Nocardia lung disease in cystic fibrosis. Pediatr Infect Dis J 2015;34(8):909–911.
58.
Rodriguez-Nava V, Durupt S, Chyderiotis S, Freydière AM, Karsenty J, de Montclos M, et al. A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients. Med Microbiol Immunol 2015;204(4):493–504.
59.
Engel TGP, Erren E, Vanden Driessche KSJ, Melchers WJG, Reijers MH, Merkus P, Verweij PE. Aerosol transmission of Aspergillus fumigatus in cystic fibrosis patients in the Netherlands. Emerg Infect Dis 2019;25(4):797–799.
60.
Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol 2014;52:161–173.
61.
Cystic Fibrosis Foundation Patient Registry Report 2015. Bethesda, MD: Cystic Fibrosis Foundation; 2016.
62.
Sabino R, Ferreira JA, Moss RB, Valente J, Veríssimo C, Carolino E, et al. Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. J Cyst Fibros 2015;14(4):474–481.
63.
Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol 2016;54(8):781–786.
64.
Baxter C, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 2013;132(3):560–566.
65.
Jones AM, Horsley A, Denning DW. What is the importance of classifying Aspergillus disease in cystic fibrosis patients? Expert Rev Respir Med 2014;8(4):389–392.
66.
Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37(Suppl 3):S225–S264.
67.
Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009;8(4):253–257.
68.
Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014;11:CD002204.
69.
Jat KR, Walia DK, Khairwa A. Use of anti-IgE treatment for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Available at: https://www.cochrane.org/CF_use-anti-ige-treatment-allergic-bronchopulmonary-aspergillosis. Accessed March 18, 2018.
70.
Reece E, Segurado R, Jackson A, McClean S, Renwick J, Greally P. Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. BMC Pulm Med 2017;17(1):70.
71.
Mouhajir A, Matray O, Giraud S, Mély L, Marguet C, Sermet-Gaudelus I, et al. Long-term Rasamsonia argillacea complex species colonization revealed by PCR amplification of repetitive DNA sequences in cystic fibrosis patients. J Clin Microbiol 2016;54(11):2804–2812.
72.
Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM. Molecular detection of CF lung pathogens: current status and future potential. J Cyst Fibros 2013;12(3):194–205.
73.
Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345–352.
74.
Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:(12 Pt 1)1550–1555.
75.
Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151(2):134–139.
76.
Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121(1):64–72.
77.
Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2(2):84–90.
78.
Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros 2015;14(6):755–762.
79.
Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182(5):627–632.
80.
VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2016;15(6):783–790.
81.
Chin M, De Zoysa M, Slinger R, Gaudet E, Vandemheen KL, Chan F, et al. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J Cyst Fibros 2015;14(4):482–489.
82.
Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62(4):360–367.
83.
Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802–808.
84.
Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax 2017;72(4):327–332.
85.
Prayle A, Watson A, Fortnum H, Smyth A. Side effects of aminoglycosides on the kidney, ear, and balance in cystic fibrosis. Thorax 2010;65(7):654–658.
86.
Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A, et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63(6):532–535.
87.
Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis –the TOPIC study: a randomized controlled trial. Lancet 2005;365(9459):573–578.
88.
Prescott WA Jr, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy 2010;30(1):95–108.
89.
Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr. Location and duration of treatment of cystic fibrosis Respiratory Exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010;182(9):1137–1143.
90.
Roehmel J, Schwarz C, Mehl A, Stock P, Staab D. Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis. J Cyst Fibros 2014;13(2):205–211.
91.
Wright MFA, Bush A, Carr S. Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis. Paediatr Respir Rev 2018;27:9–12.
92.
O'Sullivan BP, Flume PA. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med 2009;30:505–513.
93.
Main E, Grillo L, Rand S. Airway clearance strategies in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med 2015;36(2):251–266.
94.
McIlwaine M, Son NL, Chilvers M. Underlying physiological mechanisms of action for airway clearance techniques not requiring devices. Pediatr Pulmonol 2017;52(Suppl 47):140–141.
95.
Cystic fibrosis: diagnosis and management. NICE guideline 78. October 2017. Available at: https://www.nice.org.uk/guidance/ng78. Accessed September 30, 2019.
96.
McIlwaine MP, Alarie N, Davidson GF, Lands LC, Ratjen F, Milner R, et al. Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax 2013;68:746–751.
97.
Cystic Fibrosis Trust. Standards of care and good clinical practice for the physiotherapy management of cystic fibrosis, 3rd ed. April 2017. Available at: https://www.cysticfibrosis.org.uk/the-work-we-do/resources-for-cf-professionals/consensus-documents. Accessed September 30, 2019.
98.
Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241–250.
99.
Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229–240.
100.
Anderson SD, Daviskas E, Brannan JD, Chan HK. Repurposing excipients as active inhalation agents: the mannitol story. Adv Drug Deliv Rev 2018;133:45–56.
101.
Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis J Cyst Fibros 2012;11(2):78–83.
102.
Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Paediatr Respir Rev 2006;7:S215–S219.
103.
Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007;8:24–29.
104.
Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680–689.
105.
Stern RC, Boat TF, Orenstein DM, Wood RE, Matthews LW, Doershuk CF. Treatment and prognosis of lobar and segmental atelectasis in cystic fibrosis. Am Rev Respir Dis 1978;118:821–826.
106.
Barry PJ, Flume PA. Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med 2017;11(1):13–20.
107.
Weinberger M. Airway reactivity in patients with CF. Clin Rev Allergy Immunol 2002;23(1):77–85.
108.
Flume PA. Review of hemoptysis guidelines. Pediatr Pulmonol 2017;52(Suppl 47):206–207.
109.
Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA. Hemoptysis is an expected adverse event in cystic fibrosis clinical trials. J Cyst Fibros 2015;14(5):632–638.
110.
Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest 2005;128(2):729–738.
111.
Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010;182:298–306.
112.
Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 2014;13(Suppl 1):S23–S42.
113.
Lord RW, Jones AM, Webb AK, Barry PJ. Pneumothorax in cystic fibrosis: beyond the guidelines. Paed Respir Rev 2016;20(Suppl):30–33.
114.
Serra A, Polese G, Braggion C, Rossi A. Non-invasive proportional assist and pressure support ventilation in patients with cystic fibrosis and chronic respiratory failure. Thorax 2002;57:50–54.
115.
Katz ES. Cystic fibrosis and sleep. Clin Chest Med 2014;35:495–504.
116.
Tonelli AR. Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Curr Opin Pulm Med 2013;19(6):652–661.
117.
Slieker MG, van Gestel JP, Heijerman HG, Tramper-Stranders GA, van Berkhout FT, van der Ent CK, Jansen NJ. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006;32:754–758.
118.
Ratjen F. Overview of magnetic resonance imaging (MRI) in CF lung disease. Pediatr Pulmonol 2017;52(Suppl 47):202–203.
119.
Wielpütz MO, Eichinger M, Biederer J, Wege S, Stahl M, Sommerburg O, et al. Imaging of cystic fibrosis lung disease and clinical interpretation. Rofo 2016;188:834–845.
120.
Benden C, Wallis C, Owens CM, Ridout DA, Dinwiddie R. The Chrispin-Norman score in cystic fibrosis: doing away with the lateral view. Eur Respir J 2005;26:894–897.
121.
Mott LS, Park J, Gangell CL, de Klerk NH, Sly PD, Murray CP, et al. Distribution of early structural lung changes due to cystic fibrosis detected with chest computed tomography. J Pediatr 2013;163:243–248.
122.
Wielpütz MO, Mall MA. MRI accelerating progress in functional assessment of cystic fibrosis lung disease. J Cyst Fibros 2017;16(2):165–167.
123.
Roach DJ, Crémillieux Y, Fleck RJ, Brody AS, Serai SD, Szczesniak RD, et al. Ultra echo-time magnetic resonance imaging is a sensitive method for the evaluation of early cystic fibrosis lung disease. Ann Am Thorac Soc 2016;13(11):1923–1931.
124.
Altes T. Hyperpolarized gases for ventilation and gas exchange. Pediatr Pulmonol 2017;52(Suppl 47):203–204.
125.
Mentore K, Froh DK, de Lange EE, Brookeman JR, Paget-Brown AO, Altes TA. Hyperpolarized He 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol 2005:12(11):1423–1429.
126.
Harun S, Wainwright C, Klein K, Hennig S. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev 2016;20:55–66.
127.
Pittman J. Clinical application of multiple breath washout testing. Pediatr Pulmonol 2017;52(Suppl 47):122–123.
128.
Ramsey KA, Rosenow T, Turkovic L, Skoric B, Banton G, Adams AM, et al. Lung clearance index and structural lung disease on computed tomography in early cystic fibrosis. Am J Respir Crit Care Med 2016;193(1):60–67.
129.
Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guidelines for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35(Suppl 1):S1–S67.
130.
Linnane B, Collins L, Bussmann N, O'Connell NH, Dunne CP. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens. J Hosp Infect 2017;96(4):397–398.
131.
O'Malley CA. Device cleaning and infection control in aerosol therapy. Respir Care 2015;60(6):917–927.
132.
Manor E, Gur M, Geffen Y, Bentur L. Cleaning and infection control of airway clearance devices used by CF patients. Chron Respir Dis 2017;14(4):370–376.
133.
Morrell MR, Pilewski JM. Lung transplantation for cystic fibrosis. Clin Chest Med 2016;37:127–138.
134.
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report–2014; focus theme: re-transplantation. J Heart Lung Transplant 2014;33:1009–1024.
135.
Ramos KJ, Quon BS, Heltshe SL. Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States. Chest 2017;151(6):1320–1328.
136.
Ramos KJ, Quon BS, Psoter KJ, Lease ED, Mayer-Hamblett N, Aitken ML, Goss CH. Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States. J Cyst Fibros 2016;15:196–203.
137.
Ramos KJ, Somayaji R, Lease ED, Goss CH, Aitken ML. Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States. BMC Pulm Med 2017;17:21.
138.
Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, et al. The CF Lung Transplant Referral Guidelines Committee. J Cyst Fibros 2019;18(3):321–333.
139.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663–1672.
140.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508- del CFTR. N Engl J Med 2015;373(3):220–31.
141.
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 2017;377(21):2013–2023.
142.
Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, et al. Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 2017;377(21):2024–2035.
143.
Grasemann H. CFTR modulator therapy for cystic fibrosis. N Engl J Med 2017;377:2085–2088.
144.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019;381(18):1809–1819.
145.
Heijerman HG, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019 [Epub ahead of print] doi: https://doi.org/10.1016/S0140-6736(19)32597-8.
146.
Collins FS. Realizing the dream of molecularly targeted therapies for cystic fibrosis. N Engl J Med 2019;381:1863–1865.

Information & Authors

Information

Published In

cover image Respiratory Care
Respiratory Care
Volume 65Issue Number 2February 2020
Pages: 233 - 251

History

Published online: 17 December 2024
Published in print: February 2020

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Notes

Correspondence: Nelson L Turcios MD, Medical Staff Office, Robert Wood Johnson University Hospital, One Robert Wood Johnson Place, New Brunswick, NJ 08901. E-mail: [email protected].

Competing Interests

The author has disclosed no conflicts of interest.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top